Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) held an “Innovation and Technique Day” at present, through which it mentioned the way forward for its (non-generic) biopharmaceutical exercise. The corporate sees income from its three main medication: Austedo, for treating involuntary actions; migraine prevention therapy Ajovy; and long-acting schizophrenia therapy Uzedy, reaching at the very least $5 billion by 2030. This compares with $2 billion for the three merchandise mixed in 2024.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
